Newsroom

WASHINGTON D.C. — Today, Congresswoman Diana DeGette (CO-01) released the following statement after being sworn into the 119th Congress: 

"I am honored to continue representing Denver in the 119th Congress. This is a profound responsibility that I take seriously, and I remain optimistic about the work we can accomplish in a bipartisan manner. 

WASHINGTON, D.C. — Today, Congresswoman Diana DeGette (CO-01) and Congressman Larry Bucshon, M.D. (IN-08) released next steps for Cures 2.1 and the 21st Century Cures initiative. This follows a request for information in June which yielded over 300 responses and recommendations to further innovation and access to quality health care.

WASHINGTON, D.C. — Today, Congresswoman Diana DeGette (CO-01) released the following statement after she voted to pass the government funding bill.

WASHINGTON, D.C. — Today, Congresswoman Diana DeGette (CO-01) released the following statement following the vote on the National Defense Authorization Act (NDAA) in the House of Representatives. 

WASHINGTON, D.C. — Today, Congresswoman Diana DeGette (CO-01) and Congressman Gus Bilirakis (FL-12), co-chairs of the Congressional Diabetes Caucus, led 196 Members of Congress on a letter to House Leadership supporting the Special Diabetes Program (SDP) and asking for its reauthorization prior to its expiration at the end of December.   

WASHINGTON, D.C. — Today, Congresswoman Diana DeGette (CO-01) released the following statement after President-elect Donald Trump tapped Robert F. Kennedy Jr. to serve as Secretary of the Department of Health and Human Services. 

DENVER — Today, Congresswoman Diana DeGette (CO-01) released the following statement.

“I am honored to have been reelected by my constituents to continue serving them in the United States House of Representatives.

WASHINGTON, D.C., — This week, Diabetes Caucus Co-Chairs Congresswoman Diana DeGette (CO-01) and Congressman Gus Bilirakis (FL-12) sent letters to the three largest insulin producers urging them to answer questions regarding access to insulin. The letters were sent to Eli Lilly, Novo Nordisk, and Sanofi.